EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia

Eloísa Felipe Fumero iD, Carolin Walter, Joris Maximillian Frenz iD, Franca Seifert iD, Vijay Alla, Thorben Hennig iD, Linus Angenendt iD, Wolfgang Hartmann iD, Sebastian Wolf, Hubert Serve iD, Thomas Oellerich, Georg Lenz und 8 weitere

Blood · 30.05.2024 · 143 (22) · 2284-2299

DOI: 10.1182/blood.2023021640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 30.05.2024. Verfasst von Eloísa Felipe Fumero und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A, University Hospital Muenster, Muenster, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Epigenesis, Genetic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic modulation of the cell-intrinsic immune response holds promise as a therapeutic approach for leukemia. However, current strategies designed for transcriptional activation of endogenous transposons and subsequent interferon type-I (IFN-I) response, show limited clinical efficacy. Histone lysine methylation is an epigenetic signature in IFN-I response associated with suppression of IFN-I and IFN-stimulated genes, suggesting histone demethylation as key mechanism of reactivation. In this study, we unveil the histone demethylase PHF8 as a direct initiator and regulator of cell-intrinsic immune response in acute myeloid leukemia (AML). Site-specific phosphorylation of PHF8 orchestrates epigenetic changes that upregulate cytosolic RNA sensors, particularly the TRIM25-RIG-I-IFIT5 axis, thereby triggering the cellular IFN-I response-differentiation-apoptosis network. This signaling cascade largely counteracts differentiation block and growth of human AML cells across various disease subtypes in vitro and in vivo. Through proteome analysis of over 200 primary AML bone marrow samples, we identify a distinct PHF8/IFN-I signature in half of the patient population, without significant associations with known clinically or genetically defined AML subgroups. This profile was absent in healthy CD34+ hematopoietic progenitor cells, suggesting therapeutic applicability in a large fraction of patients with AML. Pharmacological support of PHF8 phosphorylation significantly impairs the growth in samples from patients with primary AML. These findings provide novel opportunities for harnessing the cell-intrinsic immune response in the development of immunotherapeutic strategies against AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteEpigenesis, GeneticHumansAnimalsHistone DemethylasesMiceInterferon Type ICell Self RenewalGene Expression Regulation, Leukemic

Substanzen

Histone DemethylasesInterferon Type I

Autor:innen und Institutionen

  • Department of Medicine A, University Hospital Muenster, Muenster, Germany.
  • Institute of Medical Informatics, Gerhard-Domagk-Institute for Pathology, University Hospital Muenster, Muenster, Germany.
  • Proteomics and Cancer Cell Signaling Group, German Cancer Research Center, Heidelberg, Germany.
  • Department of Pediatric Oncology, Hematology and Immunology, Hopp Children's Cancer Center, University of Heidelberg, Heidelberg, Germany.
  • Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland.
  • Division of Translational Pathology, Gerhard-Domagk-Institute for Pathology, University Hospital Muenster, Muenster, Germany.

ORCID-Profile: Eloísa Felipe Fumero, Joris Maximillian Frenz, Franca Seifert, Thorben Hennig, Linus Angenendt, Wolfgang Hartmann, Hubert Serve, Carsten Müller-Tidow, Otmar Huber, Martin Dugas, Matthias Mann, Ashok Kumar Jayavelu, Maria Francisca Arteaga

Zitieren

APA

Felipe Fumero, E., Walter, C., Frenz, J. M., Seifert, F., Alla, V., Hennig, T., Angenendt, L., Hartmann, W., Wolf, S., Serve, H., Oellerich, T., Lenz, G., Müller-Tidow, C., Schliemann, C., Huber, O., Dugas, M., Mann, M., Jayavelu, A. K., Mikesch, J. H., & Arteaga, M. F. (2024). Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia. Blood, 143(22), 2284-2299. https://doi.org/10.1182/blood.2023021640

Vancouver

Felipe Fumero E, Walter C, Frenz JM, Seifert F, Alla V, Hennig T, et al. Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia. Blood. 2024;143(22):2284-2299. doi:10.1182/blood.2023021640

BibTeX
@article{FelipeFumero2024,
  author = {Felipe Fumero, Eloísa and Walter, Carolin and Frenz, Joris Maximillian and Seifert, Franca and Alla, Vijay and Hennig, Thorben and Angenendt, Linus and Hartmann, Wolfgang and Wolf, Sebastian and Serve, Hubert and Oellerich, Thomas and Lenz, Georg and Müller-Tidow, Carsten and Schliemann, Christoph and Huber, Otmar and Dugas, Martin and Mann, Matthias and Jayavelu, Ashok Kumar and Mikesch, Jan-Henrik and Arteaga, Maria Francisca},
  title = {Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia},
  journal = {Blood},
  year = {2024},
  volume = {143},
  number = {22},
  pages = {2284--2299},
  doi = {10.1182/blood.2023021640}
}
Kostenlos starten →